| |
| |
|
| Insider
Information: |
Scopa James Paul |
| Relationship: |
|
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
283,083 |
|
|
Indirect Shares
|
1,195,414 |
|
|
| Direct
Value |
$1,495,000 |
|
|
|
Indirect Value
|
$468,263 |
|
|
| Total
Shares |
1,478,497 |
|
|
| Total
Value |
$1,963,263 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
2
|
|
Stock
price went up :
|
1
|
1
|
| Stock
price went down : |
1
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 206.5%
|
35.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Histogen Inc |
HSTO |
Director |
2013-07-30 |
0 |
2013-07-30 |
1,192,080 |
Premium* |
|
|
Trivascular Technologies, Inc. |
TRIV |
Director |
2014-04-22 |
0 |
2016-02-03 |
0 |
Premium* |
|
|
Adverum Biotechnologies, Inc |
ADVM |
|
2024-02-07 |
100,000 |
2024-02-07 |
3,334 |
Premium* |
|
|
Dice Therapeutics, Inc. |
DICE |
Director |
2023-08-09 |
0 |
2023-08-09 |
0 |
Premium* |
|
|
Aligos Therapeutics, Inc. |
ALGS |
|
2023-10-25 |
183,083 |
2023-10-25 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
23 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ADVM |
Adverum Biotechnologies, ... |
|
– • – |
2024-02-07 |
4 |
B |
$1.35 |
$135,000 |
D/D |
100,000 |
100,000 |
0.01 |
% |
|
| ALGS |
Aligos Therapeutics, Inc. |
|
• • – |
2023-10-25 |
4 |
A |
$0.76 |
$138,557 |
D/D |
183,083 |
183,083 |
0 |
- |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2023-08-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(25,722) |
0 |
0 |
- |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2023-08-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,199) |
0 |
0 |
- |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2023-08-02 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,420 |
25,722 |
0 |
- |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2023-07-18 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,200 |
28,142 |
0 |
- |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2023-07-11 |
4 |
GD |
$0.00 |
$0 |
I/I |
300 |
30,342 |
0 |
- |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2023-05-01 |
4 |
GA |
$0.00 |
$0 |
I/I |
6,923 |
30,642 |
0 |
- |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2023-05-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,923 |
15,199 |
0 |
- |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2023-03-17 |
4 |
S |
$29.05 |
$290,500 |
I/I |
(10,000) |
23,719 |
0 |
% |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2022-10-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
30,719 |
33,719 |
0 |
- |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2022-10-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,719 |
22,122 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
Director |
– • – |
2021-11-15 |
4 |
S |
$2.18 |
$109,000 |
I/I |
(50,000) |
3,334 |
0 |
% |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2021-09-15 |
4 |
B |
$17.00 |
$102,000 |
D/D |
6,000 |
55,841 |
2.39 |
- |
|
| DICE |
Dice Therapeutics, Inc. |
Director |
– • – |
2021-09-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
69,000 |
|
- |
|
| ADVM |
Adverum Biotechnologies, ... |
Director |
– • – |
2020-05-04 |
4 |
OE |
$6.48 |
$151,204 |
I/I |
23,334 |
53,334 |
0 |
- |
|
| ADVM |
Adverum Biotechnologies, ... |
Director |
– • – |
2020-02-14 |
4 |
B |
$13.75 |
$137,500 |
I/I |
10,000 |
30,000 |
2.1 |
% |
|
| ADVM |
Adverum Biotechnologies, ... |
Director |
– • – |
2019-05-06 |
4 |
B |
$6.71 |
$134,200 |
I/I |
20,000 |
20,000 |
2.1 |
- |
|
| TRIV |
Trivascular Technologies,... |
Director |
– • – |
2016-02-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,776,692) |
0 |
0 |
- |
|
| TRIV |
Trivascular Technologies,... |
Director |
– • – |
2014-04-22 |
4 |
A |
$0.00 |
$0 |
I/I |
1,776,692 |
1,776,692 |
0 |
- |
|
| HSTO |
Histogen Inc |
Director |
– • – |
2013-07-30 |
4 |
B |
$11.00 |
$1,817,915 |
I/I |
165,265 |
1,192,080 |
2.1 |
- |
|
| HSTO |
Histogen Inc |
Director |
– • – |
2013-07-30 |
4 |
A |
$11.00 |
$183,876 |
I/I |
16,716 |
1,026,815 |
0 |
- |
|
| HSTO |
Histogen Inc |
Director |
– • – |
2013-07-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,010,099 |
1,010,099 |
0 |
- |
|
23 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
